| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 18 | 2022 | 569 | 3.560 |
Why?
|
| Kidney Transplantation | 22 | 2024 | 621 | 2.530 |
Why?
|
| Mycobacterium tuberculosis | 12 | 2022 | 457 | 1.850 |
Why?
|
| Interferon-gamma Release Tests | 6 | 2019 | 86 | 1.700 |
Why?
|
| Coinfection | 4 | 2019 | 170 | 1.360 |
Why?
|
| Aortic Valve Insufficiency | 7 | 2025 | 138 | 1.320 |
Why?
|
| Magnetic Resonance Imaging, Cine | 10 | 2025 | 146 | 1.290 |
Why?
|
| Laparoscopy | 8 | 2024 | 502 | 1.240 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2021 | 250 | 1.050 |
Why?
|
| Middle Aged | 74 | 2025 | 25640 | 1.040 |
Why?
|
| Liver Transplantation | 10 | 2024 | 1033 | 1.020 |
Why?
|
| HIV Infections | 8 | 2021 | 1858 | 0.970 |
Why?
|
| Retrospective Studies | 62 | 2025 | 15853 | 0.960 |
Why?
|
| Graft Rejection | 11 | 2024 | 576 | 0.930 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2024 | 154 | 0.920 |
Why?
|
| Living Donors | 8 | 2024 | 111 | 0.920 |
Why?
|
| Prognosis | 26 | 2025 | 4488 | 0.900 |
Why?
|
| Hernia, Hiatal | 6 | 2021 | 54 | 0.890 |
Why?
|
| Graft Survival | 12 | 2024 | 522 | 0.890 |
Why?
|
| Predictive Value of Tests | 14 | 2024 | 2080 | 0.890 |
Why?
|
| Heller Myotomy | 2 | 2021 | 7 | 0.870 |
Why?
|
| Esophageal Achalasia | 2 | 2021 | 36 | 0.830 |
Why?
|
| Heart Transplantation | 7 | 2024 | 853 | 0.820 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 845 | 0.820 |
Why?
|
| Antitubercular Agents | 5 | 2019 | 343 | 0.810 |
Why?
|
| Robotic Surgical Procedures | 3 | 2024 | 198 | 0.800 |
Why?
|
| Humans | 135 | 2025 | 122296 | 0.800 |
Why?
|
| Aged | 48 | 2025 | 18785 | 0.790 |
Why?
|
| Male | 85 | 2025 | 59522 | 0.790 |
Why?
|
| Mass Screening | 3 | 2019 | 778 | 0.770 |
Why?
|
| Adult | 59 | 2024 | 28733 | 0.760 |
Why?
|
| Female | 85 | 2025 | 64883 | 0.750 |
Why?
|
| Texas | 16 | 2021 | 3528 | 0.740 |
Why?
|
| Pancreas Transplantation | 4 | 2024 | 36 | 0.710 |
Why?
|
| Heart-Assist Devices | 7 | 2024 | 1022 | 0.710 |
Why?
|
| Pyloromyotomy | 1 | 2019 | 3 | 0.680 |
Why?
|
| Lung Transplantation | 6 | 2024 | 316 | 0.670 |
Why?
|
| Postoperative Complications | 14 | 2024 | 2997 | 0.670 |
Why?
|
| Risk Factors | 29 | 2024 | 9902 | 0.630 |
Why?
|
| General Surgery | 4 | 2021 | 203 | 0.630 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2019 | 28 | 0.630 |
Why?
|
| Biological Assay | 1 | 2019 | 101 | 0.620 |
Why?
|
| Prevalence | 8 | 2019 | 2371 | 0.600 |
Why?
|
| Radiography, Thoracic | 2 | 2016 | 156 | 0.590 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 475 | 0.550 |
Why?
|
| Transplant Recipients | 8 | 2022 | 210 | 0.550 |
Why?
|
| Fundoplication | 7 | 2024 | 66 | 0.550 |
Why?
|
| Heart Failure | 9 | 2024 | 2125 | 0.540 |
Why?
|
| Heart Neoplasms | 3 | 2022 | 103 | 0.530 |
Why?
|
| Kidney Failure, Chronic | 6 | 2024 | 861 | 0.520 |
Why?
|
| Polyomavirus Infections | 4 | 2024 | 88 | 0.470 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 339 | 0.460 |
Why?
|
| ROC Curve | 4 | 2024 | 552 | 0.460 |
Why?
|
| Treatment Outcome | 25 | 2024 | 12045 | 0.460 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2025 | 78 | 0.460 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 228 | 0.440 |
Why?
|
| Patient Readmission | 3 | 2021 | 364 | 0.430 |
Why?
|
| Risk Assessment | 7 | 2024 | 3307 | 0.420 |
Why?
|
| Tissue Donors | 5 | 2024 | 498 | 0.420 |
Why?
|
| Follow-Up Studies | 18 | 2024 | 5013 | 0.410 |
Why?
|
| Obesity | 5 | 2022 | 2083 | 0.410 |
Why?
|
| Proportional Hazards Models | 10 | 2021 | 1298 | 0.410 |
Why?
|
| Glomerular Filtration Rate | 8 | 2024 | 480 | 0.410 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 1615 | 0.390 |
Why?
|
| Vietnam | 3 | 2019 | 44 | 0.390 |
Why?
|
| Urban Health Services | 1 | 2011 | 22 | 0.390 |
Why?
|
| Tissue and Organ Procurement | 4 | 2024 | 218 | 0.380 |
Why?
|
| Internship and Residency | 5 | 2021 | 1153 | 0.370 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 139 | 0.370 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 645 | 0.370 |
Why?
|
| Renal Insufficiency | 3 | 2022 | 232 | 0.360 |
Why?
|
| Young Adult | 15 | 2022 | 8760 | 0.350 |
Why?
|
| Prospective Studies | 16 | 2024 | 5963 | 0.350 |
Why?
|
| Organ Transplantation | 2 | 2022 | 163 | 0.350 |
Why?
|
| Adolescent | 18 | 2024 | 18940 | 0.340 |
Why?
|
| Learning | 3 | 2022 | 358 | 0.330 |
Why?
|
| Sarcoma | 2 | 2022 | 197 | 0.330 |
Why?
|
| BK Virus | 3 | 2019 | 58 | 0.320 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 112 | 0.320 |
Why?
|
| Cholangiocarcinoma | 2 | 2021 | 110 | 0.320 |
Why?
|
| Viremia | 3 | 2019 | 128 | 0.310 |
Why?
|
| Nephrectomy | 4 | 2021 | 172 | 0.310 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 56 | 0.310 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 500 | 0.310 |
Why?
|
| Tumor Virus Infections | 3 | 2019 | 135 | 0.300 |
Why?
|
| Fibrosis | 7 | 2024 | 428 | 0.300 |
Why?
|
| Health Personnel | 5 | 2019 | 500 | 0.290 |
Why?
|
| Comorbidity | 4 | 2021 | 1490 | 0.290 |
Why?
|
| Heart Diseases | 2 | 2023 | 482 | 0.280 |
Why?
|
| Stroke Volume | 6 | 2024 | 446 | 0.280 |
Why?
|
| Kidney | 6 | 2024 | 1340 | 0.280 |
Why?
|
| Databases, Factual | 4 | 2019 | 1158 | 0.280 |
Why?
|
| Antipsychotic Agents | 3 | 2015 | 367 | 0.280 |
Why?
|
| Population Surveillance | 2 | 2019 | 381 | 0.280 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2016 | 12 | 0.280 |
Why?
|
| Myocardium | 3 | 2021 | 980 | 0.270 |
Why?
|
| Thrombosis | 2 | 2022 | 515 | 0.270 |
Why?
|
| Ventricular Remodeling | 5 | 2024 | 175 | 0.260 |
Why?
|
| Hypertension | 4 | 2021 | 1274 | 0.260 |
Why?
|
| Donor Selection | 3 | 2024 | 52 | 0.260 |
Why?
|
| Age Factors | 4 | 2022 | 2777 | 0.250 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2024 | 365 | 0.250 |
Why?
|
| Latent Tuberculosis | 2 | 2016 | 83 | 0.250 |
Why?
|
| Registries | 4 | 2025 | 1367 | 0.250 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2024 | 220 | 0.250 |
Why?
|
| Infant, Newborn | 6 | 2022 | 8096 | 0.250 |
Why?
|
| Herniorrhaphy | 3 | 2021 | 80 | 0.250 |
Why?
|
| Observer Variation | 2 | 2024 | 297 | 0.250 |
Why?
|
| Isoantibodies | 3 | 2024 | 71 | 0.240 |
Why?
|
| Antigens, Bacterial | 2 | 2017 | 313 | 0.240 |
Why?
|
| Weaning | 2 | 2021 | 40 | 0.240 |
Why?
|
| Research Design | 2 | 2019 | 646 | 0.240 |
Why?
|
| Mastoidectomy | 1 | 2024 | 6 | 0.240 |
Why?
|
| Lung Diseases | 2 | 2019 | 384 | 0.240 |
Why?
|
| Cholesteatoma, Middle Ear | 1 | 2024 | 13 | 0.240 |
Why?
|
| Reproducibility of Results | 7 | 2024 | 2796 | 0.240 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 323 | 0.240 |
Why?
|
| Risperidone | 2 | 2015 | 56 | 0.230 |
Why?
|
| Infant | 7 | 2024 | 12302 | 0.230 |
Why?
|
| Child, Preschool | 8 | 2024 | 13777 | 0.230 |
Why?
|
| Cross-Sectional Studies | 7 | 2021 | 3301 | 0.230 |
Why?
|
| Area Under Curve | 3 | 2022 | 307 | 0.230 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2024 | 72 | 0.230 |
Why?
|
| Child | 14 | 2024 | 24064 | 0.230 |
Why?
|
| Logistic Models | 4 | 2018 | 1772 | 0.230 |
Why?
|
| Plasma Cells | 1 | 2024 | 47 | 0.230 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 758 | 0.220 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 56 | 0.220 |
Why?
|
| Aged, 80 and over | 8 | 2022 | 6291 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 957 | 0.220 |
Why?
|
| Time Factors | 8 | 2022 | 6182 | 0.220 |
Why?
|
| Esophageal Fistula | 1 | 2023 | 14 | 0.220 |
Why?
|
| Cicatrix | 2 | 2023 | 125 | 0.210 |
Why?
|
| Tacrolimus | 2 | 2020 | 98 | 0.210 |
Why?
|
| United States | 12 | 2024 | 10487 | 0.210 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 63 | 0.210 |
Why?
|
| Migraine Disorders | 1 | 2024 | 64 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 327 | 0.210 |
Why?
|
| Brain Death | 2 | 2021 | 55 | 0.210 |
Why?
|
| Kidney Function Tests | 2 | 2024 | 126 | 0.210 |
Why?
|
| Obesity, Morbid | 2 | 2022 | 181 | 0.210 |
Why?
|
| Faculty | 1 | 2023 | 100 | 0.210 |
Why?
|
| Length of Stay | 4 | 2024 | 1273 | 0.200 |
Why?
|
| Blood Glucose | 3 | 2022 | 1103 | 0.200 |
Why?
|
| Tuberculosis, Lymph Node | 2 | 2019 | 23 | 0.200 |
Why?
|
| Sickle Cell Trait | 1 | 2022 | 11 | 0.200 |
Why?
|
| Phlebotomy | 2 | 2019 | 17 | 0.200 |
Why?
|
| Extracellular Matrix | 2 | 2020 | 230 | 0.200 |
Why?
|
| Carcinoid Tumor | 1 | 2022 | 21 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 1204 | 0.200 |
Why?
|
| Solanum tuberosum | 1 | 2022 | 15 | 0.200 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 33 | 0.200 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 45 | 0.200 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 1386 | 0.200 |
Why?
|
| Factor Xa Inhibitors | 1 | 2022 | 63 | 0.200 |
Why?
|
| Agammaglobulinemia | 1 | 2022 | 39 | 0.200 |
Why?
|
| Odds Ratio | 2 | 2018 | 1234 | 0.190 |
Why?
|
| Bacterial Proteins | 2 | 2017 | 873 | 0.190 |
Why?
|
| Postprandial Period | 1 | 2022 | 75 | 0.190 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 41 | 0.190 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2021 | 7 | 0.190 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2021 | 34 | 0.190 |
Why?
|
| Hospitals, Public | 1 | 2021 | 38 | 0.190 |
Why?
|
| Virtual Reality | 1 | 2021 | 27 | 0.190 |
Why?
|
| Hemorrhage | 2 | 2022 | 457 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 227 | 0.180 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 1131 | 0.180 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2020 | 12 | 0.180 |
Why?
|
| Ambulatory Care | 1 | 2024 | 376 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2022 | 582 | 0.180 |
Why?
|
| Heart Ventricles | 2 | 2025 | 767 | 0.180 |
Why?
|
| Paraganglioma | 1 | 2020 | 19 | 0.180 |
Why?
|
| Education, Distance | 1 | 2021 | 64 | 0.180 |
Why?
|
| Professional Autonomy | 1 | 2020 | 27 | 0.180 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 53 | 0.180 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 15 | 0.180 |
Why?
|
| Kidney Calculi | 1 | 2020 | 40 | 0.180 |
Why?
|
| Peripheral Arterial Disease | 1 | 2024 | 266 | 0.180 |
Why?
|
| Catheter Ablation | 1 | 2023 | 229 | 0.180 |
Why?
|
| Minisatellite Repeats | 2 | 2017 | 43 | 0.180 |
Why?
|
| Public Opinion | 1 | 2020 | 54 | 0.180 |
Why?
|
| Organ Preservation | 1 | 2020 | 36 | 0.180 |
Why?
|
| Mortality | 2 | 2020 | 222 | 0.180 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 6 | 0.170 |
Why?
|
| Extracellular Fluid | 1 | 2019 | 12 | 0.170 |
Why?
|
| Palliative Care | 1 | 2024 | 424 | 0.170 |
Why?
|
| Deglutition Disorders | 1 | 2021 | 125 | 0.170 |
Why?
|
| Plasma | 1 | 2020 | 96 | 0.170 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 42 | 0.170 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2019 | 11 | 0.170 |
Why?
|
| Prediabetic State | 1 | 2020 | 57 | 0.170 |
Why?
|
| Tuberculosis, Laryngeal | 1 | 2019 | 2 | 0.170 |
Why?
|
| Tuberculosis, Oral | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 35 | 0.170 |
Why?
|
| Hypertension, Pulmonary | 2 | 2024 | 428 | 0.170 |
Why?
|
| Foreign Professional Personnel | 1 | 2019 | 2 | 0.170 |
Why?
|
| Vascular Patency | 1 | 2020 | 202 | 0.160 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 79 | 0.160 |
Why?
|
| Mental Disorders | 3 | 2015 | 822 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2023 | 384 | 0.160 |
Why?
|
| Tricuspid Valve | 1 | 2019 | 61 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 1822 | 0.160 |
Why?
|
| Sputum | 3 | 2017 | 110 | 0.160 |
Why?
|
| Teaching | 1 | 2020 | 182 | 0.160 |
Why?
|
| Biomarkers | 5 | 2021 | 2933 | 0.160 |
Why?
|
| Quetiapine Fumarate | 2 | 2015 | 14 | 0.160 |
Why?
|
| Methacholine Chloride | 1 | 2018 | 21 | 0.160 |
Why?
|
| Datasets as Topic | 1 | 2019 | 84 | 0.160 |
Why?
|
| Ciprofloxacin | 1 | 2019 | 66 | 0.160 |
Why?
|
| Attitude to Health | 1 | 2020 | 255 | 0.160 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2020 | 94 | 0.160 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 46 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 176 | 0.160 |
Why?
|
| Survival Rate | 5 | 2022 | 1997 | 0.160 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2018 | 40 | 0.160 |
Why?
|
| Contrast Media | 4 | 2023 | 459 | 0.160 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 234 | 0.160 |
Why?
|
| Primary Graft Dysfunction | 1 | 2018 | 22 | 0.160 |
Why?
|
| Angioplasty, Balloon | 1 | 2020 | 161 | 0.150 |
Why?
|
| Methylprednisolone | 1 | 2018 | 90 | 0.150 |
Why?
|
| Vascular Diseases | 1 | 2020 | 161 | 0.150 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 514 | 0.150 |
Why?
|
| Waiting Lists | 1 | 2020 | 220 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 189 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 178 | 0.150 |
Why?
|
| Telemedicine | 1 | 2024 | 422 | 0.150 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2017 | 12 | 0.150 |
Why?
|
| Troponin T | 1 | 2019 | 245 | 0.150 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 59 | 0.150 |
Why?
|
| Gadolinium | 3 | 2023 | 102 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 479 | 0.150 |
Why?
|
| Pain Management | 1 | 2019 | 167 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 215 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2017 | 212 | 0.150 |
Why?
|
| Communicable Diseases | 1 | 2020 | 163 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 711 | 0.150 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2017 | 26 | 0.140 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 2010 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3448 | 0.140 |
Why?
|
| Faculty, Medical | 1 | 2020 | 262 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2021 | 475 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 197 | 0.140 |
Why?
|
| Weight Gain | 1 | 2020 | 382 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1118 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 289 | 0.140 |
Why?
|
| Immunoassay | 1 | 2017 | 127 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 812 | 0.140 |
Why?
|
| Surgical Mesh | 1 | 2017 | 62 | 0.140 |
Why?
|
| Pandemics | 2 | 2022 | 1102 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 472 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2019 | 265 | 0.140 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 12 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 270 | 0.140 |
Why?
|
| Bradykinin | 1 | 2016 | 57 | 0.140 |
Why?
|
| Bacteriological Techniques | 1 | 2017 | 90 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 104 | 0.140 |
Why?
|
| Body Mass Index | 5 | 2022 | 1463 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.140 |
Why?
|
| Models, Biological | 1 | 2022 | 1438 | 0.140 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 117 | 0.140 |
Why?
|
| Immunologic Memory | 1 | 2017 | 180 | 0.140 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 253 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2019 | 230 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 143 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 1008 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 218 | 0.130 |
Why?
|
| Patient Selection | 1 | 2020 | 685 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 621 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2016 | 106 | 0.130 |
Why?
|
| Fever | 1 | 2018 | 295 | 0.130 |
Why?
|
| HLA Antigens | 3 | 2024 | 240 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1407 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 169 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 334 | 0.130 |
Why?
|
| HIV-1 | 1 | 2019 | 463 | 0.120 |
Why?
|
| Incidence | 5 | 2024 | 3018 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 397 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 360 | 0.120 |
Why?
|
| Quality of Life | 1 | 2024 | 1913 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 468 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.120 |
Why?
|
| Manuals as Topic | 1 | 2014 | 10 | 0.120 |
Why?
|
| Dibenzothiazepines | 1 | 2014 | 12 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 668 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1060 | 0.120 |
Why?
|
| Interferon-gamma | 1 | 2016 | 508 | 0.110 |
Why?
|
| Cohort Studies | 5 | 2022 | 4643 | 0.110 |
Why?
|
| Insulin | 2 | 2020 | 1191 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 303 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2024 | 783 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 1227 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2020 | 841 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2015 | 227 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 1099 | 0.100 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 3626 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 318 | 0.100 |
Why?
|
| Case-Control Studies | 4 | 2021 | 3229 | 0.100 |
Why?
|
| Algorithms | 2 | 2024 | 1575 | 0.090 |
Why?
|
| Proteinuria | 2 | 2022 | 110 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1250 | 0.090 |
Why?
|
| Psychiatry | 1 | 2014 | 263 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2022 | 141 | 0.090 |
Why?
|
| Pediatrics | 2 | 2024 | 1140 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 713 | 0.090 |
Why?
|
| Pneumonectomy | 2 | 2022 | 140 | 0.090 |
Why?
|
| Preoperative Period | 2 | 2021 | 83 | 0.090 |
Why?
|
| Immunization, Passive | 2 | 2020 | 118 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1283 | 0.090 |
Why?
|
| Propensity Score | 2 | 2021 | 203 | 0.090 |
Why?
|
| Transcriptome | 1 | 2016 | 904 | 0.080 |
Why?
|
| Heart Atria | 2 | 2023 | 307 | 0.080 |
Why?
|
| Recurrence | 3 | 2018 | 1413 | 0.080 |
Why?
|
| Risk | 2 | 2021 | 744 | 0.080 |
Why?
|
| Allografts | 2 | 2020 | 186 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2020 | 330 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 371 | 0.070 |
Why?
|
| Reoperation | 2 | 2023 | 807 | 0.070 |
Why?
|
| Genotype | 3 | 2017 | 2525 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 872 | 0.070 |
Why?
|
| Overweight | 2 | 2022 | 343 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2017 | 386 | 0.070 |
Why?
|
| Cholesterol | 2 | 2021 | 521 | 0.070 |
Why?
|
| Tympanoplasty | 1 | 2024 | 9 | 0.060 |
Why?
|
| Mastoid | 1 | 2024 | 24 | 0.060 |
Why?
|
| Abatacept | 1 | 2024 | 19 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2024 | 62 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2021 | 972 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2024 | 63 | 0.060 |
Why?
|
| Microscopy | 1 | 2024 | 119 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2024 | 128 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2023 | 99 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2017 | 1362 | 0.050 |
Why?
|
| Factor Xa | 1 | 2022 | 17 | 0.050 |
Why?
|
| Desensitization, Immunologic | 1 | 2024 | 95 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2024 | 215 | 0.050 |
Why?
|
| Diastole | 1 | 2023 | 170 | 0.050 |
Why?
|
| Hemolysis | 1 | 2022 | 104 | 0.050 |
Why?
|
| Faecalibacterium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Glycemic Index | 1 | 2022 | 18 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2022 | 55 | 0.050 |
Why?
|
| Surgical Stapling | 1 | 2022 | 17 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2022 | 28 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2023 | 297 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2022 | 152 | 0.050 |
Why?
|
| Esophagogastric Junction | 1 | 2021 | 27 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 1991 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 51 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2023 | 308 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 112 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 68 | 0.050 |
Why?
|
| Renal Artery | 1 | 2021 | 73 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 99 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2022 | 87 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2022 | 89 | 0.050 |
Why?
|
| Virulence Factors | 1 | 2022 | 171 | 0.050 |
Why?
|
| Rifampin | 1 | 2021 | 145 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2024 | 391 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 199 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 304 | 0.050 |
Why?
|
| Cold Ischemia | 1 | 2020 | 16 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 265 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2020 | 53 | 0.040 |
Why?
|
| Death | 1 | 2021 | 71 | 0.040 |
Why?
|
| Appendectomy | 1 | 2021 | 88 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 65 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2022 | 668 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 158 | 0.040 |
Why?
|
| Medical Futility | 1 | 2020 | 36 | 0.040 |
Why?
|
| Fasting | 1 | 2022 | 298 | 0.040 |
Why?
|
| Biopsy | 1 | 2024 | 1246 | 0.040 |
Why?
|
| Vasodilation | 1 | 2021 | 191 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 227 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 287 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 534 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 252 | 0.040 |
Why?
|
| Gadolinium DTPA | 1 | 2019 | 48 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 89 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2022 | 297 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2020 | 32 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2023 | 426 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2024 | 477 | 0.040 |
Why?
|
| Vegetables | 1 | 2022 | 257 | 0.040 |
Why?
|
| Thrombelastography | 1 | 2020 | 55 | 0.040 |
Why?
|
| Perfusion | 1 | 2020 | 196 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2020 | 189 | 0.040 |
Why?
|
| Calibration | 1 | 2019 | 83 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2019 | 93 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 315 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 300 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 231 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 560 | 0.040 |
Why?
|
| Occupational Health | 1 | 2019 | 44 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 170 | 0.040 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2018 | 11 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 237 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 321 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 187 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 657 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2019 | 78 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 85 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 659 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 723 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 2019 | 98 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 117 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 448 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 411 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2018 | 51 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 440 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 193 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 698 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 110 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 749 | 0.040 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2017 | 20 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 755 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 174 | 0.040 |
Why?
|
| Geographic Information Systems | 1 | 2017 | 39 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 609 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2024 | 691 | 0.040 |
Why?
|
| Viral Load | 1 | 2019 | 380 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 875 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1468 | 0.040 |
Why?
|
| Georgia | 1 | 2016 | 28 | 0.030 |
Why?
|
| Maryland | 1 | 2016 | 28 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 188 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 274 | 0.030 |
Why?
|
| Global Health | 1 | 2021 | 555 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 454 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2016 | 12 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 156 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 269 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2019 | 540 | 0.030 |
Why?
|
| Students, Medical | 1 | 2021 | 357 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 336 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 59 | 0.030 |
Why?
|
| Massachusetts | 1 | 2016 | 124 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 143 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 323 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1166 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 1028 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 425 | 0.030 |
Why?
|
| British Columbia | 1 | 2015 | 8 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 301 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2016 | 132 | 0.030 |
Why?
|
| Radiography | 1 | 2018 | 804 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 271 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 428 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 84 | 0.030 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2015 | 44 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2826 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 318 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1568 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 714 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1106 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 398 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 371 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2016 | 170 | 0.030 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2015 | 82 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2015 | 123 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 511 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 456 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 576 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 702 | 0.030 |
Why?
|
| Psychotic Disorders | 1 | 2015 | 139 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 347 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 860 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 473 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2014 | 202 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 294 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 2817 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 172 | 0.030 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 144 | 0.030 |
Why?
|
| Liver | 1 | 2020 | 1851 | 0.030 |
Why?
|
| Genome, Human | 1 | 2019 | 1248 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1727 | 0.030 |
Why?
|
| Genomics | 1 | 2019 | 1458 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1677 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 1314 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3074 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 676 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2014 | 631 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 620 | 0.020 |
Why?
|
| Animals | 2 | 2022 | 33721 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4151 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 4366 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 5734 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 17546 | 0.010 |
Why?
|